Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006
Prevalence of antibiotic susceptibility and resistance of Escherichia coli in acute uncomplicated cystitis in Korea: systematic review and meta-analysis
Piperacillin- tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum <TEX>${\beta}$</TEX>-lactamase-producing Escherichia coli and Klebsiella pneumoniae
Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended- spectrum-<TEX>${\beta}$</TEX>-lactamase-producing Escherichia coli isolates causing bacteremia
Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime
Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration
Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high
Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America
Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial
Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community- onset acute pyelonephritis: a prospective multicentre study
Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta- lactamase-producing Escherichia coli or Klebsiella pneumoniae
Ciprofloxacin for 7 days vs. 14 days in women with acute pyelonephritis: a randomised, open-label and double- blind, placebo-controlled, non-inferiority trial
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program
Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine
Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies
Bacteriuria in a population sample of women: 24-year follow-up study. Results from the prospective population-based study of women in Gothenburg, Sweden
Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis
A trial of levofloxacin 750 mg once daily for 5 days vs. ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis
<TEX>${\beta}$</TEX>-Lactam/ <TEX>${\beta}$</TEX>-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase- producing Escherichia coli: a post hoc analysis of prospective cohorts
